Menzer C, Menzies AM, Carlino MS, et al. - In this study, 103 individuals with metastatic melanoma with rare, activating non-V600E/K BRAF mutations that were treated with either a BRAF inhibitor (BRAFi), MEK inhibitor (MEKi), or the combination were involved in order to determine the efficiency of targeted therapy in advanced melanoma with rare BRAF mutations. It was discovered that people with rare BRAF mutations can respond to targeted therapy, nevertheless, in comparison with V600E mutated melanoma, efficiency appears to be lower. Thus, for both V600 and non-V600 mutations, combination BRAFi/MEKi seems to be the best regimen. However, due to the heterogeneity of persons with small sample sizes for some of the reported mutations, interpretation should be carried out carefully.